Regulus, Biogen Idec Ink microRNA Collaboration for Multiple Sclerosis | GenomeWeb

NEW YORK (GenomeWeb News) – Regulus Therapeutics, a developer of microRNA-based therapeutics, announced after the close of the market Wednesday that it has signed a deal with Biogen Idec to identify blood-borne miRNA biomarkers for multiple sclerosis.

In exchange for its miRNA know how, Regulus will receive undisclosed upfront and milestone payments. Biogen Idec will also make an undisclosed investment in Regulus, which was formed in 2007 as a joint venture between RNAi firm Alnylam Pharmaceuticals and antisense drug developer Isis Pharmaceuticals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.